Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia

• Status: Terminated
• Trial end date: 2015-03-01
• Target enrollment: 0
• Participant gender: All

Summary

LOP628 is an antibody-drug conjugate (ADC) consisting of an anti-cKit humanized IgG1/κ antibody conjugated to a maytansine payload via a non-cleavable linker.

LOP628 provides an opportunity to target cKit overexpressing tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals

Criteria

Inclusion Criteria:

For patients with solid tumors:

• documented cKit-positive neoplasms

• Patient must have progressive disease as defined by any of the following:

• SCLC: patient has progressed after at least 1 prior therapy

• GIST : patient has relapsed or has refractory disease, and no further approved effective therapeutic option exists

• Patients with other cKit-positive solid tumors: patient has progressed after at least one prior line of therapy and no further approved effective therapeutic option exists

• Patient has measurable disease as per RECIST v1.1 criteria

For patients with AML:

• documented cKit-positive acute myelogenous leukemia

• Consent to newly obtained bone marrow aspirate

• Patient must have progressive disease defined as relapsed or refractory non-PML AML following standard therapy or for whom no effective therapy exists.

• Blast count < 50,000/mm3

Exclusion Criteria:

For patients with solid tumors:

• Patient has central nervous system (CNS) metastatic involvement unless the CNS metastases have been previously treated and the patient is clinically stable and on a stable dose of corticosteroids for at least 4 weeks prior to enrollment.

• Patient has the presence of other clinically significant hematologic, cardiac, respiratory, gastrointestinal, renal, hepatic or neurological conditions.

• Patient has a history of serious allergic reactions, which in the opinion of the investigator may pose an increased risk of serious infusion reactions

• Patient has been previously treated with cKit directed antibodies

• Pregnant or nursing women

For patients with AML:

• Patient has received prior allogeneic bone marrow transplant (BMT).

• Patient has the presence of other clinically significant cardiac, respiratory, gastrointestinal, renal, hepatic or neurological disease

• Patient has a history of serious allergic reactions, which in the opinion of the investigator may pose an increased risk of serious infusion reactions

• Patient has been previously treated with cKit directed antibodies

• Pregnant or nursing women